TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business DENVER and CHICAGO

TriSalus Life Sciences Appoints James Alecxih

to Lead Device Technology Business

DENVER and CHICAGO, February 21, 2023 - TriSalus Life

Sciences , Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through

a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (Nasdaq: MTAC) ("MedTech"

or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President,

Device Technology Business.

Mr. Alecxih brings to TriSalus more than 30 years of experience in

product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus'

TriNav Infusion System ("TriNav "), including device engineering, device quality, sales, marketing, and market access.

Used in over 17,000 procedures, TriNav is a FDA-cleared therapy delivery technology that leverages the Pressure-Enabled Drug Delivery

("PEDD ") method to improve therapy uptake and tumor response.

"Jim's experience in successfully manufacturing, commercializing

and bringing to market novel medical devices is ideally suited to the work we are doing at TriSalus to improve treatments for patients

with liver and pancreatic cancers," said Mary Szela, CEO and President of TriSalus. "Our TriNav Infusion System is in

its growth stage, and we are confident that Jim will help us capture the opportunities ahead to take the Company to the next level. We

welcome Jim to TriSalus and I look forward to working together to improve the lives of patients through our disruptive technology."

Jim Alecxih commented, "I am excited to join TriSalus during

this pivotal period for the Company. Over the course of my career, I've worked with a number of innovative medtech companies, and

I was drawn to TriSalus because of the Company's unique platform and the ways in which its TriNav system can improve therapeutic

delivery and tumor targeting. I look forward to collaborating with Mary Szela, Dr. Katz and the rest of the team to enable better cancer

treatment for patients and drive enhanced outcomes across multiple indications."

Prior to joining TriSalus, Mr. Alecxih served as President and CEO

of ViveBio Scientific, a medical device company focused on blood transport and storage systems. Previously, he served as Chief Commercial

Officer of ViewRay, an early-stage radiation oncology company, where he managed global sales, marketing, and training. He also spent 15

years at Intuitive Surgical, Inc., maker of the da Vinci surgical and Ion endoluminal systems, where he led an 850-person sales organization

across the U.S. and Canada and exceeded revenue targets for 51 consecutive quarters.

About TriSalus and Its Proposed Business Combination with MedTech

TriSalus is an oncology company integrating immunotherapy with disruptive

delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors.

TriSalus' proprietary platform approach addresses immune dysfunction

in liver and pancreatic tumors by combining its drug delivery technology with immunotherapeutics. The TriSalus platform comprises the

TriNav Infusion System and SD-101, a class C toll-like receptor 9 (TLR9) agonist. TriNav is an FDA-cleared device that is designed

to administer established and emerging therapeutics. SD-101, the Company's investigational TLR9 agonist, is being delivered via

TriNav to selected sites, including tumors in the liver. TriNav is the latest TriSalus asset for the proprietary PEDD

method of administration which has been shown to overcome intratumoral pressure through modulation of pressure and flow to increase delivery

of therapeutic agents.

As previously announced on November 14, 2022, TriSalus has entered

into a definitive merger agreement with MedTech (the "Merger Agreement"), a publicly traded special purpose acquisition company

in connection with the proposed business combination and related transactions between the parties. Upon the closing of the transaction,

which is expected to occur in the second quarter of 2023, the combined company will be a publicly traded company and its common stock

is expected to be listed on the NASDAQ Stock Exchange under the ticker "TLSI." The transaction is subject to the satisfaction

of the necessary regulatory approvals and customary closing conditions, including the approval of MedTech's shareholders.

About MedTech Acquisition Corporation

MedTech is a blank check company formed for the purpose of effecting

a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses

or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed countries.

Changes and Additional Information in Connection with SEC Filing

The information in this communication has not been reviewed by the

U.S. Securities and Exchange Commission ("SEC") and certain information may not comply in certain respects with SEC rules.

MTAC filed with the SEC a registration statement on Form S-4 (File No. 333-269138) (as amended, the "Registration Statement"),

which includes a proxy statement/prospectus of MTAC that will be both the proxy statement to be distributed to holders of MTAC's

common stock in connection with its solicitation of proxies for the vote by MTAC's stockholders with respect to the Business Combination

and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities

to be issued in the Business Combination. The Registration Statement is not yet effective. The Registration Statement, including the proxy

statement/prospectus contained therein, when it is declared effective by the SEC, will contain important information about the Business

Combination and the other matters to be voted upon at a meeting of MTAC's stockholders to be held to approve the Business Combination

and other matters (the "Special Meeting"). MTAC may also file other documents with the SEC regarding the Business Combination.

MTAC stockholders and other interested persons are advised to read, when available, the Registration Statement, including the proxy statement/prospectus

contained therein, as well as any amendments or supplements thereto, because they will contain important information about the Business

Combination. When available, the definitive proxy statement/prospectus will be mailed to MTAC stockholders as of a record date to be established

for voting on the Business Combination and the other matters to be voted upon at the Special Meeting.

Forward-Looking Statements

This communication contains certain "forward-looking statements"

within the meaning of the United States federal securities laws regarding MTAC's or TriSalus' expectations, hopes, beliefs,

assumptions, intentions or strategies regarding the future including, without limitation, statements regarding: (i) the potential of TriSalus'

proprietary PEDD method to improve therapy uptake and tumor response and (ii) expectations for continuing program development and

capturing future sales opportunities. These forward-looking statements generally are identified by words such as "anticipate,"

"believe," "continue," "could," "estimate," "expect," "intend,"

"may," "might," "plan," "possible," "potential," "predict," "project,"

"should," "strive," "would," "will" and similar expressions or the negative or other variations

of such statements. These statements are predictions, projections and other statements about future events that are based on various assumptions,

whether or not identified in this communication and on the current expectations of MTAC's and TriSalus' respective managements

and are not predictions of actual performance and, as a result, are subject to risks and uncertainties.

Many factors could cause actual results or developments to differ materially

from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business Combination

may not be completed in a timely manner or at all, which may adversely affect the price of MTAC's securities; (ii) the risk that

the Business Combination may not be completed by MTAC's business combination deadline and the potential failure to obtain an extension

of the business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Business Combination, including

the approval of the Merger Agreement by the stockholders of MTAC, the satisfaction of the minimum cash amount following any redemptions

by MTAC's public stockholders, and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party

valuation in determining whether or not to pursue the Business Combination on the terms set forth in the Merger Agreement; (v) the occurrence

of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vi) the receipt of an unsolicited

offer from another party for an alternative transaction that could interfere with the Business Combination; (vii) the effect of the announcement

or pendency of the Business Combination on TriSalus' business relationships, operating results and business generally; (viii) risks

that the Business Combination disrupts current plans and operations of TriSalus; (ix) the outcome of any legal proceedings that may be

instituted against TriSalus or MTAC related to the Merger Agreement or the Business Combination; (x) the ability to maintain the listing

of MTAC's securities on the Nasdaq; (xi) changes in business, market, financial, political and legal conditions; (xii) unfavorable

changes in the reimbursement environment for TriSalus' products; (xiii) TriSalus' product candidates not achieving success

in preclinical or clinical trials or not being able to obtain regulatory approval, either on a timely basis or at all or subject to any

conditions that negatively impact TriSalus' ability to commercialize the applicable product candidates; (xiv) TriSalus being unable

to continue to grow TriNav sales; (xv) the size of the addressable markets for TriNav and SD-101, if successfully developed

and approved by the applicable regulatory authorities, being less than TriSalus currently estimates; (xvi) TriSalus' ability to

successfully commercialize any product candidates that it successfully develops and that are approved by applicable regulatory authorities;

(xvii) TriSalus' ability to continue to fund preclinical and clinical trials for SD-101; (xviii) TriSalus' ability to partner

with other companies; (xix) future economic and market conditions; (xx) the development, effects and enforcement of laws and regulations

affecting TriSalus' business or industry; (xxi) TriSalus' ability to manage future growth; (xxii) TriSalus' ability

to maintain and grow its market share; (xxiii) the effects of competition on TriSalus' business; (xxiv) the ability of MTAC or the

combined company to raise additional financing in connection with the Business Combination or to finance its operations in the future;

(xxv) the ability to implement business plans, forecasts and other expectations after the completion of the Business Combination, and